More than 3 million doses of Vueway (gadopiclenol), a lower-dose gadolinium contrast MRI agent used to diagnose and monitor conditions such as multiple sclerosis (MS), have been administered at more than 900 customer sites, maker Bracco Diagnostics said. Approved by the U.S. Food and Drug Administration for use in children and adults, ages 2 years and older, […]
The post Lower-dose contrast agent Vueway passes 3M doses appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com